Correlogic公司正在研究前列腺癌血液检查新方法

两项试验正在计划之中，将评估前列腺癌诊断以及鉴别无痛和进展性病变的蛋白质模式识别系统。目的是研制开发更加有效的前列腺癌血液检测方法。

一种叫做ProteomeDx的蛋白质识别系统是由Correlogic系统集团研制开发用于检测前列腺癌。该公司在这两项试验中与以下机构进行合作：健康科学大学统一服务部(USU, also in Bethesda)、Jackson军事医学进步基金会(Rockville, MD, USA)、前列腺癌研究中心、USU和该基金会的外科研究项目。USU是得到认可的联邦医学院，由美国国防部主办。Henry M. Jackson基金会是得到美国国会批准非营利组织，支持USU以及整个军事医学领域的军事教育和科研。

第一项试验将涉及2000例明确诊断为前列腺癌的患者。第二项试验将重点放在接受激进的前列腺切除手术的患者，以确定Correlogic公司的方法和技术能否被进一步用于区别大多数男性的前列腺癌是进展性还是无痛性的。Correlogic还研制开发了OvaCheck血液检测用于检查早期卵巢癌，这是经过确认的病情的终末阶段。

Correlogic系统总裁兼首席执行官Peter J.Levine说：“确定进展性和无痛性前列腺癌意味着生命与死亡、治疗与无须治疗之间的区别。”

New Studies of Prostate Cancer Blood Test
 
Two studies are being planned that will examine the use of a protein pattern recognition system for use in diagnosing prostate cancer and for use in distinguishing between indolent and aggressive disease. The goal is to develop a more-effective blood test for the detection of prostate cancer.

A protein pattern recognition system called ProteomeDx has been developed by Correlogic Systems, Inc. (Bethesda, MD, USA) for detecting prostate cancer. The company is collaborating on the two studies with the Uniformed Services University of the Health Sciences (USU, also in Bethesda), the Henry M. Jackson Foundation for the Advancement of Military Medicine (Rockville, MD, USA), and the Center for Prostate Disease Research, a program of the department of surgery at USU and the Foundation. The USU is a fully accredited federal school of medicine, operated by the U.S. Department of Defense. The Henry M. Jackson Foundation is a not-for-profit organization authorized by the U.S. Congress to support military education and research at USU and throughout the military medical community.

The first study will involve up to 2,000 men with specified prostate cancer conditions. The second study will focus on men undergoing radical prostatectomy to determine if Correlogic’s approach and technology can be extended to distinguish between aggressive and indolent disease. Currently there is no effective prospective test for determining the aggressiveness of prostate cancer in most men. Correlogic also developed the OvaCheck blood test for the early detection of ovarian cancer, which is in the final stages of an extensive validation process.

“The determination of aggressive versus indolent prostate cancer means the difference between life and death, and necessary versus unnecessary treatment,” observed Peter J. Levine, president and CEO of Correlogic Systems.